pulseData is presenting at ASN Kidney Week 2020 Reimagined
All three of pulseData's submissions have been accepted to be presented at the American Society of Nephrology's (ASN) annual conference, Kidney Week this year.
COVID-19 has affected the lives of both the patients with kidney disease and the practice of nephrology. Despite the disruptive challenges created from being at the epicenter of COVID-19 (New York, NY), The Rogosin Institute multidisciplinary care team is continuing to provide top-notch quality care powered by the pulseData intelligence platform.
We are presenting three poster presentations this year:
- Providing Multidisciplinary Renal Care in the Time of COVID-19
- What Do Data Tell Us About Patients Receiving Calcineurin Inhibitors (CNIs) and Contracting a Coronavirus
- Data-Backed Multidisciplinary Care Substantially Improves Renal Replacement Therapy Outcomes
Providing Multidisciplinary Renal Care in the Time of COVID-19
Our first abstract, Providing Multidisciplinary Renal Care in the Time of COVID-19 summarizes some of the changes created by the pandemic, particularly the trends of telehealth visits and optimal starts among the patients in The Rogosin Institute's multidisciplinary clinic [Program for Education in Advanced Kidney Disease (PEAK)]. Summary slide:
What Do Data Tell Us About Patients Receiving Calcineurin Inhibitors (CNIs) and Contracting a Coronavirus
During the initial COVID response, there was concern over whether the immunosuppressed populations would be more severely affected by COVID infections, which would affect the care of transplant nephrology patients.
For our second abstract, we identified all lab-confirmed COVID-19 positive cases since March at the Rogosin Institute via Natural Language Processing (NLP) powered expert chart review. In our series, the hospitalization rates did appear to be different (32.4% vs. 33.3%) among those who are taking calcineurin inhibitors (tacrolimus, cyclosporine, pimecrolimus) vs. non-calcineurin inhibitors.
Data-Backed Multidisciplinary Care Substantially Improves Renal Replacement Therapy Outcomes
Despite the difficulties created by the pandemic, the multidisciplinary PEAK team at the Rogosin Institute continued to provide top-notch care coordination for the CKD-to-ESRD transititon patients, being able to achieve 62% optimal start rates in our the latest data.
The efforts from the front-line clinical team at The Rogosin Institute exemplify what healthcare should be all about - proactively monitoring their patient population to maintain safety and health and allocating resources for high-risk patients while achieving best outcomes.
Their effort aligns perfectly with pulseData's mission to achieve deliver data-driven, value-based care.
pulseData is presenting at ASN Kidney Week 2020 Reimagined
COVID-19 has affected the lives of both the patients and the practice of nephrology. Despite the disruptive challenges created from being at the epicenter of COVID-19 (New York, NY), The Rogosin Institute multidisciplinary care team has been continuing to provide top-notch quality care powered by the pulseData intelligence platform
All three of pulseData's submissions have been accepted to be presented at the American Society of Nephrology's (ASN) annual conference, Kidney Week this year.
COVID-19 has affected the lives of both the patients with kidney disease and the practice of nephrology. Despite the disruptive challenges created from being at the epicenter of COVID-19 (New York, NY), The Rogosin Institute multidisciplinary care team is continuing to provide top-notch quality care powered by the pulseData intelligence platform.
We are presenting three poster presentations this year:
- Providing Multidisciplinary Renal Care in the Time of COVID-19
- What Do Data Tell Us About Patients Receiving Calcineurin Inhibitors (CNIs) and Contracting a Coronavirus
- Data-Backed Multidisciplinary Care Substantially Improves Renal Replacement Therapy Outcomes
Providing Multidisciplinary Renal Care in the Time of COVID-19
Our first abstract, Providing Multidisciplinary Renal Care in the Time of COVID-19 summarizes some of the changes created by the pandemic, particularly the trends of telehealth visits and optimal starts among the patients in The Rogosin Institute's multidisciplinary clinic [Program for Education in Advanced Kidney Disease (PEAK)]. Summary slide:
What Do Data Tell Us About Patients Receiving Calcineurin Inhibitors (CNIs) and Contracting a Coronavirus
During the initial COVID response, there was concern over whether the immunosuppressed populations would be more severely affected by COVID infections, which would affect the care of transplant nephrology patients.
For our second abstract, we identified all lab-confirmed COVID-19 positive cases since March at the Rogosin Institute via Natural Language Processing (NLP) powered expert chart review. In our series, the hospitalization rates did appear to be different (32.4% vs. 33.3%) among those who are taking calcineurin inhibitors (tacrolimus, cyclosporine, pimecrolimus) vs. non-calcineurin inhibitors.
Data-Backed Multidisciplinary Care Substantially Improves Renal Replacement Therapy Outcomes
Despite the difficulties created by the pandemic, the multidisciplinary PEAK team at the Rogosin Institute continued to provide top-notch care coordination for the CKD-to-ESRD transititon patients, being able to achieve 62% optimal start rates in our the latest data.
The efforts from the front-line clinical team at The Rogosin Institute exemplify what healthcare should be all about - proactively monitoring their patient population to maintain safety and health and allocating resources for high-risk patients while achieving best outcomes.
Their effort aligns perfectly with pulseData's mission to achieve deliver data-driven, value-based care.
